NanoViricides is trading at $1.40, up 5.26% in after-hours trading; its Ebola trial update is possible context, not a confirmed cause. - On October 13, 2026, NanoViricides said its Phase IIA trial of NV-387 oral gummies for Ebola is enrolling and progressing well. - The release described the trial design but reported no patient outcomes or efficacy results. - The announcement provided no volume or trading-activity details.